The AD risk factors/hits include high exposure to traffic-related air pollution (TRAP) and infections, as well as factors ...

Presented full dataset from first-in-human Phase 1a clinical trial demonstrating PMN310 was generally well-tolerated with monthly dosing and that PMN310 demonstrated CSF levels indicative of potential ...

Wa'el Hashad Wa'el Hashad, CEO, Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ in rare pediatric disease HLHS has ...

Presented full dataset from first-in-human Phase 1a clinical trial demonstrating PMN310 was generally well-tolerated with monthly dosing and that PMN310 demonstrated CSF levels indicative of potential ...

CT1812 slowed cognitive decline by 95% in Alzheimer’s disease patients with lower levels of plasma p-tau217 in a pre-specified analysis from ...

For more information, or to sign-up to volunteer, go to https://www.concernedforthehungry.org. Fall-La-Palooza event aims to ...

The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the interim report for the period January - September, and the third quarter, 2024. The full interim report, which ...

Julianna LeMieux and Uduak Thomas discuss their time at the ASHG meeting in Denver and some of the trends that they are ...

The platform presentation entitled, “The MSA Atrophy Index: A Marker of Clinical Progression in Multiple System Atrophy”, was presented by Paula Trujillo Diaz, PhD, Research Assistant Professor, ...

Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...

Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease .

MALVERN, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) ('Annovis' or the 'Company'), a clinical-stage drug ...